Drug intelligence / Profile preview

PolipillV1

Development stage
Unknown
Modality
Small Molecules
Administration
Oral
01

Overview

PolipillV1 is a fixed-dose combination pharmaceutical drug designed to improve treatment compliance in patients at high cardiovascular risk or with established cardiovascular disease. It combines four well-known medications: aspirin (75mg), simvastatin (40mg), lisinopril (10mg), and atenolol (50mg). Aspirin acts as an antiplatelet agent by irreversibly inhibiting cyclooxygenase enzymes, primarily COX-1, to reduce thromboxane A2 production. Simvastatin is a statin that lowers cholesterol by inhibiting HMG-CoA reductase, a key enzyme in cholesterol synthesis. Lisinopril is an ACE inhibitor, reducing blood pressure by blocking the conversion of angiotensin I to angiotensin II. Atenolol is a selective beta-1 adrenergic receptor antagonist, which decreases heart rate and cardiac output, thereby lowering blood pressure. This combination aims to provide comprehensive cardiovascular protection by addressing multiple risk factors simultaneously.

Other names
poli pill version 1
02

Targets

ACE (Angiotensin Converting Enzyme)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)ADRB1 (β1)PGHS-1 (Prostaglandin G/H Synthase 1)

Beyond the preview

Go deeper on PolipillV1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on PolipillV1.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call